제넥신
Financials
Valuation Metrics
제넥신's Market Cap is ₩1277B. At end of 2025 it was ₩2134B. Ranked #1124 of 2,421 in KR market (top 46%), #591 of 1,640 on KOSDAQ (top 36%), #127 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 55%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 127.74B KRW | KR#1,124/2,421 Sec#127/231 |
| Revenue | 4.97B KRW | KR#2,344/2,421 Sec#197/231 |
| Net Income | -32.30B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 331.75B KRW | KR#983/2,421 Sec#61/231 |
| Net Assets | 200.12B KRW | KR#947/2,421 Sec#66/231 |
| Employees | 89 | KR#1,732/2,421 Sec#137/231 |
| Value | ||
| P/B | 0.64x | KR#1,036/2,421 Sec#53/231 |
| P/S | 25.71x | KR#2,347/2,421 Sec#186/231 |
| FCF Yield | -34.69% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -16.14% | KR#2,042/2,421 Sec#157/231 |
| ROA | -9.74% | KR#2,095/2,421 Sec#157/231 |
| Op. Margin | -798.72% | KR#2,378/2,421 Sec#211/231 |
| Revenue Growth | 229.89% | KR#32/2,421 Sec#10/231 |
| Financial Health | ||
| Debt Ratio | 65.78% | KR#1,160/2,421 Sec#138/231 |
| Total Debt | 114.87B KRW | KR#681/2,421 Sec#41/231 |
| FCF | -44.32B KRW | KR#2,062/2,421 Sec#204/231 |
| Cash | 10.08B KRW | KR#1,694/2,421 Sec#144/231 |
| Current Ratio | 0.27x | KR#2,214/2,421 Sec#215/231 |
| Performance | ||
| 1Y Return | -48.15% | KR#2,017/2,421 Sec#179/231 |
| 1M Return | 13.10% | KR#379/2,421 Sec#23/231 |
| From 52W High | -62.55% | KR#1,949/2,421 Sec#156/231 |
| 1Y MDD | -69.08% | KR#1,954/2,421 Sec#166/231 |
| Trading | ||
| Volume | 80,112 shares | KR#891/2,421 Sec#90/231 |
| Trading Value | 225.4M KRW | KR#1,225/2,421 Sec#126/231 |
| Foreign Own. | 3.91% | KR#1,069/2,421 Sec#97/231 |
| Per Share | ||
| EPS | -709 KRW | KR—/2,421 Sec—/231 |
| BPS | 4,394 KRW | KR#1,591/2,421 Sec#113/231 |
Company Info
Established in 1999, the company is a biopharmaceutical enterprise listed on the KOSDAQ market since 2009. Through a 2024 merger with EPD Bio Co., Ltd., it secured the bioPROTAC platform technology EPDeg™. The company is developing various therapeutics, including anticancer immunotherapeutics (GX-I7), utilizing hyFc fusion protein and DNA vaccine manufacturing technologies. It aims for technology transfer through joint development and clinical trials with global pharmaceutical companies to secure future growth engines. Genexine is headquartered in Gangseo-gu, Seoul Metropolitan City.